{"id":"W4297981952","doi":"10.1016/j.annonc.2022.08.079","title":"LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Cohort; Adverse effect; Clinical endpoint; Pembrolizumab; Cisplatin; Gastroenterology; Oncology; Urology; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009155793,0.0006808953,0.001168421,0.0002595242,0.0002866007,0.001069239,0.0006305075,0.0006739631,0.004696636],"category_scores_gemma":[0.0004824978,0.0003255913,0.001269131,0.000381873,0.0004231619,0.0005002472,0.0002569851,0.002097704,0.0009443356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111382,"about_ca_system_score_gemma":0.001239947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002379505,"about_ca_topic_score_gemma":0.006479598,"domain_scores_codex":[0.9996933,0.0001486606,0.00001293917,0.00004420106,0.00002847338,0.00007240182],"domain_scores_gemma":[0.9997308,0.00004437158,0.00005355042,0.00002621913,0.00001844813,0.0001265988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.777613,0.02012758,0.01688712,0.0008504277,0.00311883,0.0002083276,0.0002030802,0.00235913,0.03822983,0.0005600383,0.01207681,0.1277657],"study_design_scores_gemma":[0.4285575,0.4629682,0.07082329,0.0002048794,0.004194268,0.0006258709,0.0002010257,0.002597505,0.01015779,0.0004992777,0.019095,0.0000753687],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885144,0.002710131,0.0002500196,0.000469765,0.0001222741,0.0005435708,0.003604251,0.00009675556,0.003688788],"genre_scores_gemma":[0.9893292,0.001648045,0.000507283,0.0005334121,0.0001083398,0.0003912558,0.00446585,0.00003755707,0.00297895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004696636,"threshold_uncertainty_score":0.01571184,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04378439509686054,"score_gpt":0.3740006686367162,"score_spread":0.3302162735398557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}